Burning Rock Biotech Ltd

Burning Rock Biotech develops and provides next-generation sequencing diagnostic solutions for cancer therapy selection, minimal residual disease monitoring, and early cancer detection. Its offerings include tissue and liquid biopsy testing panels, such as OncoScreen and OncoCompass, automated library preparation systems, and diagnostic reagent kits covering multiple solid tumor types like lung, colorectal, and breast cancers. The company serves oncologists, healthcare facilities, cancer patients, and pharmaceutical companies, supporting clinical trials through central laboratory testing and companion diagnostics development.

The enterprise operates primarily in China via two complementary distribution channels: a central processing laboratory and an in-hospital network. Under its in-hospital framework, it collaborates with 94 hospitals across 43 Chinese cities, with 20 domestic hospitals adopting its automated library preparation equipment. Burning Rock Biotech maintains its corporate headquarters and principal executive offices in Guangzhou, China, with a registered office in the Cayman Islands.

Summary of the business section of Burning Rock Biotech's latest annual report, written by StockData.